Cystatin B as a potential diagnostic biomarker in ovarian clear cell carcinoma

International Journal of Oncology

Volumn 46, Issue 4, 2015, Pages 1573-1581

  Takaya, Akane ^a   Peng, Wei Xia ^a   Ishino, Kousuke ^a   Kudo, Mitsuhiro ^a   Yamamoto, Tetsushi ^b   Wada, Ryuichi ^a   Takeshita, Toshiyuki ^a   Naito, Zenya ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b KINKI UNIVERSITY   (Japan)

Author keywords

Annexin a4; Clear cell carcinoma; Cystatin B; Epithelial ovarian cancer; Formalinfixed paraffin embedded tissue; Shotgun proteomics

Indexed keywords

CYSTATIN B; LIPOCORTIN 4; PROTEIN; CSTB PROTEIN, HUMAN; CULTURE MEDIUM; TUMOR MARKER;

ARTICLE; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER TISSUE; CELL LYSATE; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CULTURE MEDIUM; DIAGNOSTIC TEST ACCURACY STUDY; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; OVARIAN CLEAR CELL CARCINOMA; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR DIFFERENTIATION; UPREGULATION; WESTERN BLOTTING; ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; BLOOD; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; OVARIAN NEOPLASMS; PATHOLOGY; PHARMACOLOGY; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; ANNEXIN A4; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; CULTURE MEDIA, CONDITIONED; CYSTATIN B; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MASS SPECTROMETRY; MIDDLE AGED; OVARIAN NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84923098813     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.2858     Document Type: Article

References (41)

1. DU BOIS A, LÜCK HJ, MEIER W, et al: A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as frst-line treatment of ovarian cancer. J Natl Cancer Inst 95: 1320-1329, 2003.
2. KITAWAKI J, ISHIHARA H, KOSHIBA H, et al: Usefulness and limits of ca-125 in diagnosis of endometriosis without associated ovarian endomeriomas. Hum reprod 20: 1999-2003, 2005.
3. OZOLS RF, BUNDY BN, GREER BE, et al: Phase? trial of carbo-platin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage? ovarian cancer: A gynecologic oncology group study. J Clin Oncol 21: 3194-3200, 2003.
4. UEKURI C, SHIGETOMI H, ONO S, SASAKI Y, MATSUURA M and KOBAYASHI H: Toward an understanding of the pathophysiology of clear Cell carcinoma of the ovary (review). Oncol Lett 6: 1163-1173, 2013.
5. OLD WM, MEYER-ARENDT K, AVELINE-WOLF L, et al: Comparison of label-free methods for quantifying human proteins by shotgun proteomics. Molecular & cellular proteomics. Mol Cell Proteomics 4: 1487-1502, 2005.
6. TOYAMA A, SUZUKI A, SHIMADA T, et al: Proteomic characterization of ovarian cancers identifying annexin-a4, phosphoserine aminotransferase, cellular retinoic acid-binding protein 2, and serpin B5 as histology-specifc biomarkers. Cancer Sci 103: 747-755, 2012.
7. YAMAMOTO T, KUDO M, PENG WX and NAITO Z: Analysis of protein expression regulated by lumican in Panc-1 cells using shotgun proteomics. Oncol rep 30: 1609-1621, 2013.
8. WANG JJ, LIU Y, ZHENG Y, LIN F, CAI GF and YAO XQ: Comparative proteomics analysis of colorectal cancer. Asian Pac J Cancer Prev 13: 1663-1666, 2012.
9. Zhu Y, Wu R, Sangha N, et al. Classifcations of ovarian Cancer tissues by proteomic patterns. Proteomics 6: 5846-5856, 2006.
10. MORGAN TM, SEELEY EH, FADARE O, CAPRIOLI RM and CLARK PE: Imaging the clear Cell renal Cell carcinoma proteome. Jurol 189: 1097-1103, 2013.
11. TAN Y, MA SY, WANG FQ, et al: Proteomic-based analysis for identification of potential serum biomarkers in gallbladder cancer. Oncol rep 26: 853-859, 2011.
12. JIANG X, JIANG X, FENG S, TIAN R, YE M and ZOU H: Development of effcient protein extraction methods for shotgun proteome analysis of formalin-fxed tissues. J Proteome Res 6: 1038-1047, 2007
13. SPRUNG RW JR, BROCK JW, TANKSLEY JP, et al: Equivalence of protein inventories obtained from formalin-fxed paraffn-embedded and frozen tissue in multidimensional liquid chromatography-tandem mass spectrometry shotgun proteomic analysis. Mol Cell Proteomics 8: 1988-1998, 2009
14. KAWAMURA T, NOMURA M, TOJO H, et al: Proteomic analysis of laser-microdissected paraffn-embedded tissues: (1) stage-related protein candidates upon non-metastatic lung adenocarcinoma. J Proteomics 73: 1089-1099, 2010.
15. BATEMAN NW, SUN M, BHARGAVA R, et al: Diffetential proteomic analysis of late-stage and recurrent breast Cancer from formalin-fxed paraffn-embedded tissues. J Proteome Res 10: 1323-1332, 2011.
16. NAIDOO K, JONES R, DMITROVIC B, et al: Proteome of formalin-fxed paraffn-embedded pancreatic ductal adenocarcinoma and lymph node metastases. J Pathol 226: 756-763, 2012.
17. RODRIGUEZ-RIGUEIRO T, VALLADARES-AYERBES M, HAZ-CONDE M, et al: A novel procedure for protein extraction from formalin-fixed paraffn-embedded tissues. Proteomics 11: 2555-2559, 2011
18. YAMADA K, TACHIBANA T, HASHIMOTO H, et al: Establishment and characterization of Cell lines derived from serous adenocarcinoma (jHoS-2) and clear Cell adenocarcinoma (jHoc-5, jHoc-6) of human ovary. Hum Cell 12: 131-138, 1999
19. HAYASHI M, OKUDA T, CHIBA H, C AGATSUKA M and OKAI T: The analysis of toll-like receptor signal pathway in human ovarian Cancer cells. J Showa Med Assoc 70: 211-221, 2010.
20. YAMAMOTO T, MATSUDA Y, KAWAHARA K, NAITO Z and I SHIWATA T: Keratinocyte growth factor stimulates growth of MIa Paca-2 cells through extracellular signal-regulated kinase phosphorylation. Oncol Lett 3: 307-310, 2012.
21. BLUEMLEIN K and RALSER M: Monitoring protein expression in whole-cell extracts by targeted label-and standard-free lc-MS/MS. Nat Protoc 6: 859-869, 2011.
22. ZYBAILOV B, COLEMAN MK, FLORENS L and WASHBURN MP: Correlation of relative abundance ratios derived from peptide ion chromatograms and spectrum counting for quantitative proteomic analysis using stable isotope labeling. anal chem 77: 6218-6224, 2005
23. DE HOON MJ, IMOTO S, NOLAN J and MIYANO S: Open source clustering software. Bioinformatics 20: 1453-1454, 2004
24. SALDANHA AJ: Java treeview-extensible visualization of microarray data. Bioinformatics 20: 3246-3248, 2004
25. COTOI CG, KHORSANDI SE, PLESEA IE and QUAGLIA A: Whole-genome DaSl Gene expression profiling of hepatocellular carcinoma sub-populations isolated by laser microdissection on formalin-fxed and paraffn-embedded liver tissue samples. Rom J Morphol f mbryol 53: 893-902, 2012.
26. KOTORASHVILI A, RAMNAUTH A, LIU R, et al: Effective Dna/rna co-extraction for analysis of micro cNAs, mrnas, and genomic dnA from formalin-fxed paraffn-embedded specimens. PLoS One 7: E34683, 2012.
27. NAKANISHI Y, SHIMIZU T, TSUJINO I, et al: Semi-nested real-time reverse transcription polymerase chain reaction methods for the successful quantitation of cytokeratin mrna expression levels for the subtyping of non-small-cell lung carcinoma using paraffn-embedded and microdissected lung biopsy specimens. Acta Histochem cytochem 46: 85-96, 2013.
28. FELDMAN AS, BANYARD J, WU CL, MCDOUGAL WS and ZETTER BR: Cystatin B as a tissue and urinary biomarker of bladder Cancer recurrence and disease progression. Clin Cancer Res 15: 1024-1031, 2009.
29. LEE M-J, YU G-R, PARK S-H, et al: Identifcation of cystatin B as a potential serum marker in hepatocellular carcinoma. Clin Cancer Res 14: 1080-1089, 2008.
30. RIVENBARK AG and COLEMAN WB: Epigenetic regulation of cystatins in cancer. front Biosci (landmark ed) 14: 453-462, 2009.
31. KEPPLER D: Towards novel anti-cancer strategies based on cystatin function. Cancer Lett 235: 159-176, 2006.
32. KOS J and LAH TT: Cysteine proteinases and their endogenous inhibitors: Target proteins for prognosis, diagnosis and therapy in Cancer (review). Oncol rep 5: 1349-1361, 1998.
33. GASHENKO EA, LEBEDEVA VA, BRAK I V, TSYKALENKO EA, VINOKUROVA GV and KOROLENKO TA: Evaluation of serum proca-thepsin B, cystatin B and cystatin c as possible biomarkers of ovarian cancer. Int J circumpolar Health 72: 21215, 2013.
34. MASUISHI Y, ARAKAWA N, KAWASAKI H, MIYAGI E, HIRAHATA F and HIRANO H: Wild-type p53 enhances annexin? Gene expression in ovarian clear Cell adenocarcinoma. FEBS J 278: 1470-1483, 2011.
35. KIM A, ENOMOTO T, SERADA S, et al: Enhanced expression of annexin a4 in clear Cell carcinoma of the ovary and its association with chemoresistance to carboplatin. Int J Cancer 125: 2316-2322, 2009.
36. MOGAMI T, YOKOTA N, ASAI-SATO M, et al: Annexin a4 is involved in proliferation, chemo-resistance and migration and invasion in ovarian clear Cell adenocarcinoma cells. Plos one 8: E80359, 2013.
37. KAJIHARA H, YAMADA Y, KANAYAMA S, et al: Clear Cell carcinoma of the ovary: Potential pathogenic mechanisms (review). Oncol rep 23: 1193-1203, 2010.
38. TSUCHIYA A, SAKAMOTO M, YASUDA J, et al: Expression profling in ovarian clear Cell carcinoma: Identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear Cell carcinoma. Am J Pathol 163: 2503-2512, 2003.
39. DUNCAN R, CARPENTER B, MAIN LC, TELFER C and MURRAY GI: Characterisation and protein expression profling of annexins in colorectal cancer. Br J Cancer 98: 426-433, 2008.
40. LIN L-L, HUANG H-C and JUAN H-F: Revealing the molecular mechanism of gastric Cancer marker annexin a4 in Cancer Cell proliferation using exon arrays. PloS one 7: E44615, 2012.
41. ZIMMERMANN U, BALABANOV S, GIEBEL J, et al: Increased expression and altered location of annexin? in renal clear Cell carcinoma: A possible role in tumour dissemination. Cancer lett 209: 111-118, 2004.